Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models

Glioblastomas are malignant brain tumors which remain lethal due to their aggressive and invasive nature. The standard treatment combines surgical resection, radiotherapy, and chemotherapy using Temozolomide, albeit with a minor impact on patient prognosis (15 months median survival). New therapies...

Full description

Bibliographic Details
Main Authors: Mélodie Davy, Laurie Genest, Christophe Legrand, Océane Pelouin, Guillaume Froget, Vincent Castagné, Tristan Rupp
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
brain cancer
glioblastoma
glioma
preclinical models
tumor progression
Fingolimod
Online Access:https://www.mdpi.com/2072-6694/15/18/4478

Internet

https://www.mdpi.com/2072-6694/15/18/4478

Similar Items